Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Testosterone

×

Overview

What is Testosterone?



What does Testosterone look like?



What are the available doses of Testosterone?

Testosterone topical solution is a topical solution available as a:

Each metered-dose pump is supplied with an applicator.

What should I talk to my health care provider before I take Testosterone?

How should I use Testosterone?

Testosterone topical solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone:

Limitations of use:

Prior to initiating testosterone topical solution, confirm the diagnosis of hypogonadism by ensuring that serum testosterone concentrations have been measured in the morning on at least two separate days and that these serum testosterone concentrations are below the normal range.


What interacts with Testosterone?

Sorry No Records found


What are the warnings of Testosterone?

Sorry No Records found


What are the precautions of Testosterone?

Sorry No Records found


What are the side effects of Testosterone?

Sorry No records found


What should I look out for while using Testosterone?

Men with carcinoma of the breast or known or suspected carcinoma of the prostate (,)

Pregnant or breastfeeding women. Testosterone may cause fetal harm (, ,)


What might happen if I take too much Testosterone?


How should I store and handle Testosterone?

Keep testosterone topical solution out of reach of children. Store upright at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].Used testosterone topical solution bottles and applicators should be discarded in household trash in a manner that prevents accidental exposure of children or pets. Keep testosterone topical solution out of reach of children. Store upright at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].Used testosterone topical solution bottles and applicators should be discarded in household trash in a manner that prevents accidental exposure of children or pets. Keep testosterone topical solution out of reach of children. Store upright at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].Used testosterone topical solution bottles and applicators should be discarded in household trash in a manner that prevents accidental exposure of children or pets. Trandolapril tablets, USP are supplied as follows: 1 mg tablet - White to off-white, round, convex tablet with "" bisect "" on one side and " " on the other side. NDC 16252-541-30                Bottles of 30 2 mg tablet - White to off-white, round, convex tablet with "" on one side and " " on the other side. NDC 16252-542-90                Bottles of 90 4 mg tablet - White to off-white, round, convex tablet with "" on one side and " " on the other side. NDC 16252-543-90                Bottles of 90 Dispense in well-closed container with safety closure.Trandolapril tablets, USP are supplied as follows: 1 mg tablet - White to off-white, round, convex tablet with "" bisect "" on one side and " " on the other side. NDC 16252-541-30                Bottles of 30 2 mg tablet - White to off-white, round, convex tablet with "" on one side and " " on the other side. NDC 16252-542-90                Bottles of 90 4 mg tablet - White to off-white, round, convex tablet with "" on one side and " " on the other side. NDC 16252-543-90                Bottles of 90 Dispense in well-closed container with safety closure.Trandolapril tablets, USP are supplied as follows: 1 mg tablet - White to off-white, round, convex tablet with "" bisect "" on one side and " " on the other side. NDC 16252-541-30                Bottles of 30 2 mg tablet - White to off-white, round, convex tablet with "" on one side and " " on the other side. NDC 16252-542-90                Bottles of 90 4 mg tablet - White to off-white, round, convex tablet with "" on one side and " " on the other side. NDC 16252-543-90                Bottles of 90 Dispense in well-closed container with safety closure.Trandolapril tablets, USP are supplied as follows: 1 mg tablet - White to off-white, round, convex tablet with "" bisect "" on one side and " " on the other side. NDC 16252-541-30                Bottles of 30 2 mg tablet - White to off-white, round, convex tablet with "" on one side and " " on the other side. NDC 16252-542-90                Bottles of 90 4 mg tablet - White to off-white, round, convex tablet with "" on one side and " " on the other side. NDC 16252-543-90                Bottles of 90 Dispense in well-closed container with safety closure.Trandolapril tablets, USP are supplied as follows: 1 mg tablet - White to off-white, round, convex tablet with "" bisect "" on one side and " " on the other side. NDC 16252-541-30                Bottles of 30 2 mg tablet - White to off-white, round, convex tablet with "" on one side and " " on the other side. NDC 16252-542-90                Bottles of 90 4 mg tablet - White to off-white, round, convex tablet with "" on one side and " " on the other side. NDC 16252-543-90                Bottles of 90 Dispense in well-closed container with safety closure.Trandolapril tablets, USP are supplied as follows: 1 mg tablet - White to off-white, round, convex tablet with "" bisect "" on one side and " " on the other side. NDC 16252-541-30                Bottles of 30 2 mg tablet - White to off-white, round, convex tablet with "" on one side and " " on the other side. NDC 16252-542-90                Bottles of 90 4 mg tablet - White to off-white, round, convex tablet with "" on one side and " " on the other side. NDC 16252-543-90                Bottles of 90 Dispense in well-closed container with safety closure.Trandolapril tablets, USP are supplied as follows: 1 mg tablet - White to off-white, round, convex tablet with "" bisect "" on one side and " " on the other side. NDC 16252-541-30                Bottles of 30 2 mg tablet - White to off-white, round, convex tablet with "" on one side and " " on the other side. NDC 16252-542-90                Bottles of 90 4 mg tablet - White to off-white, round, convex tablet with "" on one side and " " on the other side. NDC 16252-543-90                Bottles of 90 Dispense in well-closed container with safety closure.Trandolapril tablets, USP are supplied as follows: 1 mg tablet - White to off-white, round, convex tablet with "" bisect "" on one side and " " on the other side. NDC 16252-541-30                Bottles of 30 2 mg tablet - White to off-white, round, convex tablet with "" on one side and " " on the other side. NDC 16252-542-90                Bottles of 90 4 mg tablet - White to off-white, round, convex tablet with "" on one side and " " on the other side. NDC 16252-543-90                Bottles of 90 Dispense in well-closed container with safety closure.


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Endogenous androgens, including testosterone and dihydrotestosterone (DHT), are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include the growth and maturation of prostate, seminal vesicles, penis and scrotum; the development of male hair distribution, such as facial, pubic, chest and axillary hair; laryngeal enlargement, vocal cord thickening, alterations in body musculature and fat distribution. Testosterone and DHT are necessary for the normal development of secondary sex characteristics.

Male hypogonadism, a clinical syndrome resulting from insufficient secretion of testosterone, has two main etiologies. Primary hypogonadism is caused by defects of the gonads, such as Klinefelter's Syndrome or Leydig cell aplasia, whereas secondary hypogonadism is the failure of the hypothalamus (or pituitary) to produce sufficient gonadotropins (FSH, LH).

Non-Clinical Toxicology
Men with carcinoma of the breast or known or suspected carcinoma of the prostate (,)

Pregnant or breastfeeding women. Testosterone may cause fetal harm (, ,)

Monitor patients with benign prostatic hyperplasia (BPH) for worsening of signs and symptoms of BPH ()

Avoid unintentional exposure of women or children to testosterone topical solution. Secondary exposure to testosterone can produce signs of virilization. Testosterone topical solution should be discontinued until the cause of the virilization is identified (, )

Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE) have been reported in patients using testosterone products. Evaluate patients with signs or symptoms consistent with DVT or PE. ()

Some postmarketing studies have shown an increased risk of myocardial infarction and stroke associated with use of testosterone replacement therapy. ()

Exogenous administration of testosterone may lead to azoospermia ()

Edema with or without congestive heart failure, may be a complication in patients with preexisting cardiac, renal, or hepatic disease ().

Sleep apnea may occur in those with risk factors ()

Monitor serum testosterone, prostate specific antigen (PSA), liver function, lipid concentrations, hematocrit and hemoglobin periodically (,, , )

Testosterone topical solution is flammable until dry ()

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).